Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 3
2011 3
2012 2
2013 1
2015 1
2016 2
2017 1
2018 5
2019 2
2020 3
2021 3
2022 2
2023 5
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Abril-Rodriguez G, et al. Among authors: nowicki ts. Nat Cancer. 2020;1(1):46-58. doi: 10.1038/s43018-019-0003-0. Epub 2019 Dec 9. Nat Cancer. 2020. PMID: 34368780 Free PMC article.
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.
Nowicki TS, Hu-Lieskovan S, Ribas A. Nowicki TS, et al. Cancer J. 2018 Jan/Feb;24(1):47-53. doi: 10.1097/PPO.0000000000000303. Cancer J. 2018. PMID: 29360728 Free PMC article. Review.
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
Nguyen VP, Campbell KM, Nowicki TS, Elumalai N, Medina E, Baselga-Carretero I, DiNome ML, Chang HR, Oseguera DK, Ribas A, Glaspy JA. Nguyen VP, et al. Among authors: nowicki ts. Cancer Res Commun. 2023 Aug 23;3(8):1628-1637. doi: 10.1158/2767-9764.CRC-23-0145. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37621406 Free PMC article. Clinical Trial.
Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.
Nowicki TS, Peters CW, Quiros C, Kidd CK, Kawakami M, Klomhaus AM, Baselga-Carretero I, Kaplan-Lefko P, Macabali MH, Perez Garcilazo I, Berent-Maoz B, Comin-Anduix B, Ribas A. Nowicki TS, et al. Cancer Immunol Res. 2023 Dec 1;11(12):1589-1597. doi: 10.1158/2326-6066.CIR-23-0577. Cancer Immunol Res. 2023. PMID: 37871333 Free PMC article.
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Abril-Rodriguez G, et al. Among authors: nowicki ts. Nat Cancer. 2020 Feb;1(2):264. doi: 10.1038/s43018-020-0025-7. Nat Cancer. 2020. PMID: 35122015 No abstract available.
Ancestral diversity is limited in published T cell receptor sequencing studies.
Huang YN, Peng K, Popejoy AB, Hu J, Nowicki TS, Gold SM, Quintana-Murci L, Fuentes-Guajardo M, Shugay M, Greiff V, Burkhardt AM, Alachkar H, Mangul S. Huang YN, et al. Immunity. 2021 Oct 12;54(10):2177-2179. doi: 10.1016/j.immuni.2021.09.015. Immunity. 2021. PMID: 34644550 Free article. No abstract available.
Rigorous benchmarking of T-cell receptor repertoire profiling methods for cancer RNA sequencing.
Peng K, Nowicki TS, Campbell K, Vahed M, Peng D, Meng Y, Nagareddy A, Huang YN, Karlsberg A, Miller Z, Brito J, Nadel B, Pak VM, Abedalthagafi MS, Burkhardt AM, Alachkar H, Ribas A, Mangul S. Peng K, et al. Among authors: nowicki ts. Brief Bioinform. 2023 Jul 20;24(4):bbad220. doi: 10.1093/bib/bbad220. Brief Bioinform. 2023. PMID: 37291798 Free PMC article.
30 results